Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNQ3 | O43525 | 2/20 | 0.55 |
| ▸ | KCNQ2 | O43526 | 2/20 | 0.55 |
| ▸ | KCNE1 | P15382 | 2/20 | 0.55 |
| ▸ | KCNQ1 | P51787 | 2/20 | 0.55 |
| ▸ | KCNQ5 | Q9NR82 | 1/20 | 0.55 |
| ▸ | RAF1 | P04049 | 12/20 | 0.54 |
| ▸ | BRAF | P15056 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.51 |
| ▸ | KCNK9 | Q9NPC2 | 1/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | BTK | Q06187 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CSF1R | P07333 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29427247 | 1.00 | KCNQ3 (0.55) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL29427245 | 0.86 | RAF1 (0.53) | RAF1BRAF | |
| SCHEMBL17591647 | 0.86 | RAF1 (0.53) | RAF1BRAF | |
| SCHEMBL29427239 | 0.86 | RAF1 (0.53) | RAF1BRAF | |
| SCHEMBL2887561 | 0.85 | BRAF (0.58) | RAF1BRAFMEN1HTTRAB9A | |
| SCHEMBL29536884 | 0.85 | BRAF (0.58) | RAF1BRAFMEN1HTTRAB9A | |
| SCHEMBL25421306 | 0.83 | PTGS1 (0.54) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL29537019 | 0.83 | PTGS1 (0.54) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL5489272 | 0.82 | MEN1 (0.55) | KCNQ3KCNQ2KCNE1KCNQ1KCNQ5 | |
| SCHEMBL22612940 | 0.82 | LCK (0.44) | RAF1KCNK3KCNK9LCKKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11667634-B2 | Inhibitors of RAF kinases | KINNATE BIOPHARMA INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-20230046018-A1 | BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR | QILU PHARMACEUTICAL CO., LTD. (CN) | 2023-02-16 | — | — | US | disclosed |
| CN-114072148-A | Inhibitors of RAF kinase | 金耐特生物制药公司 | 2022-02-18 | — | — | CN | disclosed |
| CN-108699065-B | Tricyclic compounds and compositions as kinase inhibitors | 诺华股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| CN-108467369-B | Biaryl amide compounds as kinase inhibitors | 诺华股份有限公司 | 2021-08-20 | — | — | CN | disclosed |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-08-12 | — | — | US | disclosed |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | Pierre Fabre Médicament (FR) | 2021-08-12 | — | — | US | disclosed |
| EP-3390404-B1 | TRICYCLIC COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2021-07-21 | — | — | EP | disclosed |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2016-02-11 | — | — | US | disclosed |
| US-9242969-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242969-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-9242969-B2 | Biaryl amide compounds as kinase inhibitors | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| EP-2970216-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | Novartis AG (CH) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014151616-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-25 | — | — | WO | disclosed |
| US-20140275003-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275003-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
| US-20140275003-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667634-B2 | Inhibitors of RAF kinases | BRAF, RAF1, NRAS | KCNQ3 4449/4885KCNQ2 4268/4885KCNE1 4105/4885 |
| US-20140275003-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | KCNQ3 3048/4885KCNQ2 2678/4885KCNE1 3211/4885 |
| US-20230046018-A1 | BIARYL COMPOUND AS PAN-RAF KINASE INHIBITOR | BRAF, RAF1, ARAF | KCNQ3 2811/4885KCNQ2 3291/4885KCNE1 2859/4885 |
| US-20210246135-A1 | INHIBITORS OF RAF KINASES | BRAF, RAF1, NRAS | KCNQ3 4449/4885KCNQ2 4268/4885KCNE1 4105/4885 |
| US-20160038504-A1 | BIARYL AMIDE COMPOUNDS AS KINASE INHIBITORS | BRAF, RAF1, NRAS | KCNQ3 3048/4885KCNQ2 2678/4885KCNE1 3211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.